Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): Final results of the global real-world study, TAURUS.

Cristina SantoroBeng FuhPhu Quoc LePhilip MaesRubén BerruecoMaria-Eva Mingot-Castellano Sylvia von MackensenClaudia TueckmantelJose Francisco Cabre-MarquezMichael Wang

Published in: European journal of haematology (2022)

These data show that a smooth transition is observed when switching to octocog alfa from a previous FVIII treatment, with no safety issues and stable bleeding rates in a real-world setting of patients with moderate-to-severe haemophilia A.

Keyphrases

replacement therapy
atrial fibrillation
early onset
high intensity
big data
machine learning
drug induced